Regeneron Pharms (NASDAQ: REGN)‘s stock had its “buy” rating reiterated by equities research analysts at TheStreet in a research note issued to investors on Wednesday.
The analysts wrote, “Regeneron Pharmaceuticals (REGN) has been reiterated by TheStreet Ratings as a buy with a ratings score of B . The company’s strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”
A number of other analysts have also recently weighed in on REGN. Analysts at Zacks reiterated a “neutral” rating on shares of Regeneron Pharms in a research note to investors on Monday, February 18th. They now have a $173.00 price target on the stock. Separately, analysts at Deutsche Bank reiterated a “buy” rating on shares of Regeneron Pharms in a research note to investors on Monday, February 11th. They now have a $190.00 price target on the stock. Finally, analysts at Robert W. Baird reiterated an “outperform” rating on shares of Regeneron Pharms in a research note to investors on Friday, January 25th. They now have a $205.00 price target on the stock.
Eight equities research analysts have rated the stock with a buy rating, one has assigned an overweight rating, and nine have issued a hold rating to the company’s stock. The company presently has a consensus rating of “overweight” and an average price target of $184.54.
Shares of Regeneron Pharms traded up 1.96% during mid-day trading on Wednesday, hitting $164.80. Regeneron Pharms has a 52 week low of $102.02 and a 52 week high of $188.95. The stock’s 50-day moving average is currently $170.0. The company has a market cap of $15.928 billion and a P/E ratio of 23.93.
Regeneron Pharms last issued its quarterly earnings data on Thursday, February 14th. The company reported $1.47 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.11 by $0.36. The company had revenue of $415.00 million for the quarter, compared to the consensus estimate of $392.64 million. During the same quarter last year, the company posted ($0.37) earnings per share. Regeneron Pharms’s revenue was up 237.1% compared to the same quarter last year. Analysts expect that Regeneron Pharms will post $4.11 EPS for the current fiscal year.
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.
To view TheStreet’s full report, visit www.thestreetratings.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
